

NecstGen Announces Major Milestone – GMP Manufacturing License

Today, the NecstGen team is happy to announce that it has received its GMP Manufacturing License!

LEIDEN, SOUTH HOLLAND, NETHERLANDS, December 5, 2022 /EINPresswire.com/ -- 5 December 2022, Leiden, today the NecstGen team is happy to announce that it has received its GMP Manufacturing License. Farmatec, part of the Dutch Ministry of Health, Welfare and Sport has granted NecstGen its license for the GMP manufacturing of Advanced Therapy Medicinal Products.

Throughout the last year, NecstGen has finalised the construction of its brand-new 4,000 m² GMP facility on the Leiden Bio Science Park. In November, a GMP inspection was carried out by the Dutch Health and Youth Care Inspectorate (IGJ). Following the positive outcome of this inspection, NecstGen has received the license for the GMP manufacturing of ATMPs from Farmatec/CIBG, the executive body of the Ministry of Health, Welfare and Sport (VWS).

Paul Bilars, CEO said "This is a culmination, a stamp of approval, on the work of our dedicated team. It is a symbol of the high standards we aim to maintain daily, and the trust placed within us as an organisation. With the determination of our expert team and many others it has been possible to meet the standards for achieving our Manufacturing License."

The license allows NecstGen to manufacture and release Cell and Gene Therapies for patients. As a Centre of Excellence for Cell and Gene Therapies, NecstGen aims to accelerate the development and manufacturing of this next generation of promising therapies by providing critical services. Through its GMP facility containing 13 cleanrooms, NecstGen can support academic and industrial therapy developers, offering flexibility in both scale and modality.

[email us here](#)

Tristan Pritchard-Meaker

NecstGen BV

+31 6 25344672

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/604869241>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.